Inflammatory Myositis Market to Accelerate Substantially at a CAGR of 11.7% by 2032, Predicts DelveInsight

Key Takeaways from the Inflammatory Myositis Market Report Key Takeaways from the Inflammatory Myositis Market Report Discover which therapies are expected to grab the major inflammatory myositis market share @Inflammatory Myositis Market Report Inflammatory Myositis Overview Inflammatory myositis, often known as myositis, is a rare autoimmune condition characterized by muscular inflammation. Polymyositis, dermatomyositis, inclusion body myositis, and necrotizing autoimmune...

Key Takeaways from the Inflammatory Myositis Market Report

Discover which therapies are expected to grab the major inflammatory myositis market share @ Inflammatory Myositis Market Report

Inflammatory Myositis Overview

Inflammatory myositis, often known as myositis, is a rare autoimmune condition characterized by muscular inflammation. Polymyositis, dermatomyositis, inclusion body myositis, and necrotizing autoimmune myopathy are all examples of inflammatory myositis. The exact cause of inflammatory myositis is unknown, although it is thought to be related to an aberrant immunological response in which the body's immune system destroys its own muscle tissue by mistake. 

Muscle weakness, muscle soreness, difficulty swallowing, weariness, and, in certain cases, skin rashes are the most common symptoms of inflammatory myositis. The severity of the inflammatory myositis symptoms varies and may worsen over time. Dermatomyositis is characterized by skin rashes, which frequently include the face and upper torso. A medical history, physical examination, blood tests, electromyography (EMG), muscle biopsy, and imaging techniques such as MRI are commonly used to identify inflammatory myositis.

Inflammatory Myositis Epidemiology Segmentation

DelveInsight estimates that there were approximately 184Kdiagnosed prevalent cases of inflammatory myositis in the 7MM in 2022.

According to DelveInsight estimates, assessments indicate that within the age groups of 0–17 years, 18–44 years, 45–64 years, and 65 years and above, a greater prevalence of diagnosed cases of inflammatory myositis was observed among individuals aged 45–64 years with 77.6K cases in 2022 in the 7MM.

The inflammatory myositis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Inflammatory Myositis Treatment Market 

Inflammatory myositis is usually treated with a mix of pharmaceutical treatments and supportive measures. The primary goals of inflammatory myositis treatment are to reduce inflammation, manage symptoms, preserve muscle function, and avoid potential consequences. Currently, therapeutic techniques for inflammatory myositis include a combination of immunosuppressive medications such as corticosteroids and disease-modifying anti-rheumatic drugs (DMARDs) such as immunosuppressive agents. Biologic drugs, physical therapy, and supportive measures are also used. 

Biologic drugs such as rituximab or tocilizumab, which precisely targets immune system components to decrease inflammation, may be used in patients with severe or resistant inflammatory myositis.In more severe or resistant cases, drugs such as cyclophosphamide or cyclosporine may be administered to dampen the immune response and reduce inflammation. If corticosteroids, immunosuppressive drugs, and IVIG fail to relieve symptoms, IV cyclophosphamide can be used as a last-resort treatment. Prograf capsules (generic name: tacrolimus) are an immunosuppressive medicine extensively used in the treatment of a variety of medical diseases, including myositis, in Japan.

The US Food and Drug Administration (FDA) has approved OCTAGAM 10% (Immune Globulin Intravenous [Human]) for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease. The US FDA has approved ACTHAR Gel (repository corticotropin injection) for use in individuals with two subtypes of idiopathic inflammatory myopathies (IIMs), dermatomyositis (DM) and polymyositis (PM). ACTHARGel is a naturally occurring blend of adrenocorticotropic hormone analogues and pituitary peptides.

To know more about inflammatory myositis treatment, visit @ Inflammatory Myositis Treatment Drugs 

Key Inflammatory Myositis Therapies and Companies

Learn more about the FDA-approved drugs for inflammatory myositis @ Drugs for Inflammatory Myositis Treatment 

Inflammatory Myositis Market Dynamics

The inflammatory myositis market is expected to change in the coming years. The therapeutic landscape is abundant in terms of assessing the efficacy, safety, and tolerability of innovative medications in patients with inflammatory myositis and its different forms. Rising data on the general prevalence of inflammatory myositis and its subtypes is predicted to dramatically increase the patient pool.

Moreover, the inflammatory myositis companies and academics are working to assess challenges and seek opportunities that could influence inflammatory myositis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition. Inflammatory myositis companies are involved in developing inflammatory myositis therapies. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the inflammatory myositis market in the 7MM.

However, certain factors may affect the growth of the inflammatory myositis market. The growing pipeline is gloomy, with a scarcity of effective late-stage drugs. The existing therapeutic options are linked with concerning side effects such as renal toxicity, nausea, osteoporosis, pulmonary toxicity, and others. Moreover, the inflammatory myositis market growth may be offset by unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the inflammatory myositis market growth.

 

Scope of the Inflammatory Myositis Market Report

Discover more about inflammatory myositis drugs in development @ Inflammatory Myositis Clinical Trials

Table of Contents

 

Related Reports

Myositis Pipeline

Myositis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myositis companies, including GlaxoSmithKline, Corbus Pharmaceuticals, Abcuro, Inc., Orphazyme, Bristol-Myers Squibb, Kezar Life Sciences, Inc., Horizon Therapeutics, Viela Bio, Paean Biotechnology Inc., Alexion Pharmaceuticals, Janssen Biotech, CSL Behring, Pfizer, Roche, among others.

Inclusion Body Myositis Epidemiology Forecast

Inclusion Body Myositis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted inclusion body myositis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Inclusion Body Myositis Market

Inclusion Body Myositis Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key inclusion body myositis companies, including Acceleron Pharma Inc, KPI Therapeutics Inc, Milo Biotechnology LLC, Nobelpharma Co Ltd, Orphazyme ApS, Ultragenyx Pharmaceutical Inc, among others.

Inclusion Body Myositis Pipeline

Inclusion Body Myositis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key inclusion body myositis companies, including Acceleron Pharma Inc, KPI Therapeutics Inc, Milo Biotechnology LLC, Nobelpharma Co Ltd, Orphazyme ApS, Ultragenyx Pharmaceutical Inc, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg 

 

View original content:https://www.prnewswire.co.uk/news-releases/inflammatory-myositis-market-to-accelerate-substantially-at-a-cagr-of-11-7-by-2032--predicts-delveinsight-301879314.html